Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.31 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.31 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.31 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.31 |
| ▸ | DUT | P33316 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1591858 | 1.00 | SLC28A1 (0.31) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL860749 | 0.90 | SLC28A1 (0.32) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL17807707 | 0.90 | SLC28A1 (0.32) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL15782468 | 0.90 | SLC28A1 (0.32) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL10238922 | 0.90 | SLC28A1 (0.32) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL17191717 | 0.83 | SLC28A1 (0.34) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL14946371 | 0.82 | SLC28A1 (0.32) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL17191712 | 0.81 | MEN1 (0.32) | DUT | |
| SCHEMBL10238959 | 0.79 | DUT (0.36) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL16503451 | 0.79 | DUT (0.36) | SLC28A1SLC28A2SLC29A1SLC28A3DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9061041-B2 | 2′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20140161770-A1 | 2'-CYANO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF USEFUL FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140154211-A1 | 2'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME LLC | 2014-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140161770-A1 | 2'-CYANO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF USEFUL FOR THE TREATMENT OF VIRAL DISEASES | HCCS, NSUN2, PNP | SLC28A1 7/4885SLC28A2 6/4885SLC29A1 5/4885 |
| US-20140154211-A1 | 2'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | SLC29A2, SLC29A1, SLC28A2 | SLC28A1 4/4885SLC28A2 3/4885SLC29A1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.